News
The former official, Vinay Prasad, had been on the job three months and had recently come under attack by conservative ...
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
45m
India Today on MSNWhat forced Vinay Prasad to exit top job at US FDA in just 3 monthsIndian-origin scientist Vinay Prasad resigned as the FDA's vaccine and gene therapy chief in just three months after backlash ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
The president overruled his HHS secretary and FDA chief, four people with knowledge of the decision tell POLITICO.
16h
TipRanks on MSNSarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy UseShares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...
Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure. A ...
Sarepta (NASDAQ:SRPT) stock, Replimune (NASDAQ:REPL) stock and Capricor (CAPR) stock surge as FDA's biologics head exits abruptly. Read more here.
Sarepta Therapeutics Inc. shares rose sharply early Tuesday after US regulators reversed course and recommended that patients ...
Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.
Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results